Semaglutide After Pancreatitis: A Case

A case report published on 16 September 2026 in JCEM Case Reports describes a 39-year-old man given semaglutide after six separate hospitalizations for hypertriglyceridemia-induced pancreatitis over nine years^[1]. His triglycerides had peaked at 2,329 mg/dL, more than thirteen times the upper limit of normal, and statins, fibrates and high-dose omega-3 fatty acids had all failed to keep him out of hospital^[1]. Ten months after starting semaglutide, his triglycerides were normal, his insulin was gone, and he had not had a seventh episode.

That is one patient. Clinicians have historically been reluctant to prescribe GLP-1 receptor agonists like semaglutide to anyone with a pancreatitis history, because acute pancreatitis is a listed warning on the drug's own label^[2]. The authors, a team at Monash Health in Melbourne, frame their report as a direct challenge to that caution, not as proof it was wrong.

What the case describes

The patient, a 39-year-old Chinese man, was referred to a multidisciplinary metabolic dysfunction-associated liver disease (MASLD, the current clinical term for fatty liver driven by metabolic disease) clinic at Monash Health after his sixth episode of pancreatitis in nine years^[1]. Alongside the recurring pancreatitis, he had poorly controlled type 2 diabetes, frequent hypoglycemia (low blood sugar episodes, an unusual combination alongside poorly controlled diabetes), and steatotic liver disease with moderate scarring^[1].

In August 2024, the clinic's endocrinologist started semaglutide and titrated it up to the maximum 1 mg weekly dose over three months, with the endocrinology, gastroenterology and hepatology teams monitoring him jointly^[1]. Over the following ten months his weight fell from 84.1 kg to 75.5 kg, his triglycerides dropped from a peak of 2,329 mg/dL to 213 mg/dL, his liver scarring improved on elastography, and his insulin was stopped entirely^[1]. No further pancreatitis episode occurred through his most recent follow-up, roughly 22 months after his first visit to the clinic^[1].

Why this used to be off the table

The caution around GLP-1 drugs and pancreatitis dates back to early postmarketing safety reports that raised concern about a link between incretin-based therapies and the pancreas, with proposed mechanisms including changes in pancreatic duct cells and altered gallbladder function^[1]. The concern was taken seriously enough that it became a standing part of the prescribing conversation. It remains on the label today: the current Ozempic prescribing information warns that "acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC," and instructs prescribers to watch for persistent abdominal pain and to stop the drug if pancreatitis is suspected^[2].

The wider evidence has been shifting for a while

This case did not appear in isolation. A 2025 review in the Cleveland Clinic Journal of Medicine, by Mehta, Lomeli and Pantalone, looked at the accumulated trial and observational data and concluded that large meta-analyses do not show a statistically significant rise in pancreatitis with GLP-1 receptor agonist therapy as a class^[3]. The same review reports a Cleveland Clinic retrospective look at 161 patients with a prior pancreatitis episode who went on to receive a GLP-1 drug: only 10% had a recurrence, and more than half of those recurrences were traced to causes other than the medication itself^[3]. Its authors argue the risk tracks more closely with how fast someone loses weight than with the drug class itself, and recommend screening, counseling and paced weight loss rather than a blanket refusal.

That review does not overturn the label, and it is not new data of its own. It is a synthesis, built on studies its authors did not run, and its conclusion is a recommendation for more careful case-by-case judgment rather than a green light. Held next to it, the Monash case reads less like an outlier and more like a documented example of the pattern the reviewers were describing.

What one case can and cannot show

A case report sits at the bottom of the evidence pyramid. There was no comparison group, no randomization, and no way to separate the effect of semaglutide from the effect of close multidisciplinary follow-up, from the weight loss itself, or from whatever changed in this specific patient's diet and habits once a specialist clinic was watching him closely every few weeks. The authors say so themselves: they describe the follow-up as relatively short and note it limits any judgment about how durable the triglyceride reduction will be, or whether pancreatitis stays away over years rather than months.

They also flag what they did not do. There was no formal genetic testing to rule out a hereditary lipid disorder, and they recommend that clinicians managing similar patients consider lipoprotein phenotyping, a laboratory workup that characterizes the specific fat particles driving someone's high triglycerides, before assuming the picture is the same in every patient.

What this means

Read narrowly, this is a single well-documented patient whose numbers moved in the right direction on semaglutide after conventional therapy had run out of road. Read alongside the Cleveland Clinic review, it fits a pattern researchers have been describing for a while: the old blanket caution against GLP-1 drugs after pancreatitis is being replaced, in the literature at least, with a more selective approach built around specialist oversight and a slower pace of weight loss. Pancreatitis is still a listed warning on the label, and it is not going away because of one case.

This article is educational and is not medical advice. Whether a GLP-1 receptor agonist makes sense for someone with a pancreatitis history is a decision for a clinician who knows that patient's full record, not a conclusion to draw from a single published case.